Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension

Journal of Human Hypertension

Volumn 10, Issue 11, 1996, Pages 729-734

  Himmelmann, A ^a   Svensson, A ^a   Bergbrant, A ^a   Hansson, L ^a,b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Angiotensin II antagonist; Left ventricular mass; Losartan; Renin angiotensin aldosterone system

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LOSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE HYPERTROPHY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; MALE; MIDDLE AGED; SWEDEN; TETRAZOLES;

EID: 0030472291     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Levy D et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
2. Koren MJ et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.
3. Muiesan ML et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13: 1091-1095.
4. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients - a meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
5. Eberhardt RT, Kevak RM, Kang PM, Frishman WH. Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. J Clin Pharmacol 1993; 33: 1023-1038.
6. Timmermans PBMWM et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharm Rev 1993; 46: 205-225.
7. Siegl PKS. Discovery of losartan, the first specific nonpeptide angiotensin II receptor antagonist. J Hypertens 1993; 11 (Suppl 3): S19-S22.
8. Schoenberger JA for the Losartan Research Group. Losartan with hydrochlorothiazide in the treatment of hypertension. J Hypertens 1995; 13 (Suppl 1): S43-S47.
9. Dahlöf B et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8: 578-583.
10. Lappe JT et al. Efficacy and tolerability of losartan potassium (MK-954, DuP 753), compared to felodipine ER in elderly patients. J Hypertens 1994; 12 (Suppl 3): 80.
11. Gradman AH et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-1350.
12. Soffer BA et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-117.
13. Kjeldsen SE et al. Treatment with the angiotensin II antagonist losartan in 180 patients with severe hypertension. Am J Hypertens 1994; 7 (Part 2): 33A.
14. Gazdick LP et al. A double blind, randomized, parallel, active-controlled study to evaluate the antihypertensive efficacy and safety of losartan in patients with severe hypertension. Am J Hypertens 1994; 7 (Part 2): 100A.
15. Velvis M et al. Safety and efficacy of losartan potassium/hydrochlorothiazide combination tablet in patients with severe hypertension. Am J Hypertens 1995; 8 (Part 2): 192.
16. 1 receptor. Am J Hypertens 1992; 5: 276-280.
17. Linz W, Henning R, Schölkens BA. ACE inhibition and angiotensin II receptor antagonism on development and regression of cardiac hypertrophy in rats. J Hypertens 1991; 9 (Suppl 6): S400-S401.
18. Ruzicka M, Leenan FHH. Renin-angiotensin system and minoxidil-induced cardiac hypertrophy in rats. Am J Physiol 1993; 265: H1551-H1556.
19. Quing G, Garcia R. Chronic captopril and losartan (DuP 753) administration in rats with high-output heart failure. Am J Physiol 1992; 263 (Heart Circ Physiol): H833-H840.
20. Himmelmann A et al. Losartan in essential hypertension: Effects on blood pressure and left ventricular mass. High Blood Press 1995; 4: 242-248.
21. Devereux RB. Evaluation of cardiac structure and function by echocardiography and other non-invasive techniques. In: Laragh JH, Brenner BM, (eds). Hypertension: pathophysiology, diagnosis, and treatment. Raven Press Ltd: New York, 1990, pp 1479-1492.
22. Sahn DJ, DeMaria A, Kisslo J, Weyman A. The Committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
23. Devereux RB et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison of necropsy findings. Am J Cordiol 1986; 57: 450-458.
24. Dahlöf B. Structural cardiovascular changes in essential hypertension. Studies on the effects of antihypertensive therapy. Blood Press 1992; 1 (Suppl 6): 1-75.
25. Goa KL, Wagstaff AJ. Losartan Potassium. A Review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51: 820-845.
26. Yoshinaga K et al. Efficacy, safety and usefulness of MK-954 (losartan potassium), angiotensin II receptor antagonist on essential hypertension in the long-term treatment. Rinsho Iyaku 1995; 11: 175-207.
27. Hansson L. Left ventricular hypertrophy. High Blood Press 1993: 2 (Suppl 1): 2-4.
28. Laragh JH, Sealey JE. The renin-angiotensin-aldosterone system in hypertensive disorders: a key to two forms of arteriolar vasoconstriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis. In: Larah JH, Brenner BM (ed). Hypertension: pathophysiology, diagnosis and management. Raven Press Ltd: New York, 1990, pp 1329-1348.
29. Abdelrahman AM, Burrell LM, Johnston CI. Blockade of the renin-angiotensin system at different sites: effect on rening, angiotensin and aldosterone. J Hypertens 1993; 11 (Suppl 3): S23-S26.
30. Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993; 11 (Suppl 3): S13-S18.
31. Scicli AG. Increases in cardiac kinins as a new mechanism to protect the heart. Hypertension 1994; 23: 419-421.
32. Linz W, Schölkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effects of ramipril. Br J Phmarcol 1992; 105: 771-772.
33. Linz W, Gohlke P, Unger T, Schölkens BA. Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction. Arch Mal Cæur 1995; 88 (II): 31-34.
34. McDonald KM et al. Early ventricular remodeling after myocardial damage and its attenuation by converting enzyme inhibition. Trans Assoc Am Physicians 1990; 103: 229-235.
35. McDonald KM et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995; 91: 2043-2048.
36. 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation 1994; 90: 3034-3046.
37. Devereux RB, Dahlöf B. Criteria for an informative trial on left ventricular hypertrophy regression. J Hum Hypertens 1994; 8: 735-739.